Adma Biologics (ADMA) Income from Continuing Operations (2011 - 2025)
Adma Biologics (ADMA) posted Income from Continuing Operations of 133277000.0 for Q4 2025, down 465.86% on a QoQ basis from 36428000.0 in Q3 2025, and down 367.26% year-over-year from 49868000.0 in Q4 2024.
Adma Biologics (ADMA) Income from Continuing Operations (2011 - 2025) Analysis & Trends
Adma Biologics' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 133277000.0 for Q4 2025.
- Quarterly Income from Continuing Operations fell 367.26% year-over-year to 133277000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 35726000.0 (down 126.34% YoY) and the FY2025 annual result came in at 35726000.0, down 126.34% from the prior year.
- Income from Continuing Operations was 133277000.0 for Q4 2025 at Adma Biologics, down from 36428000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 49868000.0 in Q4 2024 and bottomed at 133277000.0 in Q4 2025.
- A 5-year average of 2278076.45 and a median of 6580000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations surged 1299.96% — and 2025, when it sank 367.26%.
- Adma Biologics' Income from Continuing Operations stood at 25145684.0 in 2021, then rose by 25.89% to 18636035.0 in 2022, then surged by 156.85% to 10594000.0 in 2023, then jumped by 370.72% to 49868000.0 in 2024, then plunged by 367.26% to 133277000.0 in 2025.
- Business Quant data shows ADMA's Income from Continuing Operations at 133277000.0 in Q4 2025, 36428000.0 in Q3 2025, and 34219000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Adma Biologics | 1.99 Bn | 1.91 Bn | 88.82 Mn | -133.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -133.28 Mn |
| Sep 30, 2025 | 36.43 Mn |
| Jun 30, 2025 | 34.22 Mn |
| Mar 31, 2025 | 26.90 Mn |
| Dec 31, 2024 | 49.87 Mn |
| Sep 30, 2024 | 35.91 Mn |
| Jun 30, 2024 | 32.06 Mn |
| Mar 31, 2024 | 17.81 Mn |
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 2.57 Mn |
| Jun 30, 2023 | -6.37 Mn |
| Mar 31, 2023 | -6.79 Mn |
| Dec 31, 2022 | -18.64 Mn |
| Sep 30, 2022 | -14.89 Mn |
| Jun 30, 2022 | -13.75 Mn |
| Mar 31, 2022 | -18.17 Mn |
| Dec 31, 2021 | -25.15 Mn |
| Sep 30, 2021 | -17.73 Mn |
| Jun 30, 2021 | -18.82 Mn |
| Mar 31, 2021 | -18.34 Mn |